This project aims to understand how platinum-based chemotherapy affects hearing function in cancer patients from different socioeconomic backgrounds in the North West of England. Platinum-based chemotherapy drugs, particularly cisplatin, are highly toxic, causing permanent damage to the hearing system. Patients from deprived backgrounds face additional risk factors, including limited healthcare access, greater occupational noise exposure, and poorer overall health, making them more vulnerable to hearing loss. This is especially concerning as hearing loss is linked to cognitive decline and, when combined with chemotherapy-related cognitive dysfunction (“chemo brain”), may further increase dementia risk. It is expected that patients from the most deprived backgrounds (e.g., quintile 1) would experience greater hearing loss than those from more affluent backgrounds (e.g., quintile 5). By identifying disparities in hearing loss, this research will help guide future hearing screening and intervention strategies for cancer patients.